Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone and Mitoxantrone and PEG-asparaginase& and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblastic Leukaemia
Protocol ID
CFZ2008 / 20140106
Disease (Sub Disease)
Acute Lymphoblastic Leukaemia (ALL)
Diagnosis Stage
Relapse/refractory
Location
NSW, QLD, VIC, WA
Sponsor
Amgen
Collaborators
Therapeutic Advances in Childhood Leukemia & Lymphoma
Innovative Therapies For Children with Cancer Consortium
Trial Status
Open
Sites
Queensland Children's Hospital
Sydney Children's Hospital
Royal Children's Hospital
Perth Children's Hospital
Children's Hospital at Westmead
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
1 Month to 21 Years
International registry ID's
NCT02303821
Back to Registry
Study Title Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone and Mitoxantrone and PEG-asparaginase& and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblastic Leukaemia
Protocol ID CFZ2008 / 20140106
Disease (Sub Disease) Acute Lymphoblastic Leukaemia (ALL)
Diagnosis Stage Relapse/refractory
Location NSW / QLD / VIC / WA
Sponsor Amgen
Collaborators Therapeutic Advances in Childhood Leukemia & Lymphoma/ Innovative Therapies For Children with Cancer Consortium/
Links https://clinicaltrials.gov/ct2/show/NCT02303821
Trial Status Open
Trial Open Date 10/09/2015
Sites Queensland Children's Hospital / Sydney Children's Hospital / Royal Children's Hospital/ Perth Children's Hospital/ Children's Hospital at Westmead
Study Type Treatment
Phase Phase 1/2
Age Eligibility 1 Month to 21 Years
International registry ID's NCT02303821